Granata Bio
Granata Bio is a reproductive-health biopharmaceutical company founded in 2018 and headquartered in the United States, focused on expanding access to fertility and IVF therapeutics across North America. The company identifies, licenses, and develops biopharmaceuticals spanning the in-vitro fertilization medication lifecycle from ovarian stimulation through luteal phase support, and is advancing a clinical pipeline that includes the Phase III GRACE Study. Granata Bio has raised over $30M, including a $14M Series A led by GV (Google Ventures) and a subsequent $15M Series A+. It operates a corporate and clinical web presence only and does not currently publish a public developer platform, API, or machine-readable interface; this profile captures its identity and web properties within the API Evangelist network.
Granata Bio is profiled on the APIs.io network. Tagged areas include Company, Life Sciences, Biopharmaceutical, Reproductive Health, and Fertility.
Granata Bio’s developer surface includes engineering blog, support, and 5 more developer resources.
Kin Score
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Access & Security 1
Authentication, authorization, and security posture
Operate 1
Status, limits, changes, and where to get help
Commercial 1
Pricing, plans, and the legal terms of use
Company 4
The organization behind the API